FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond
Journal of Hepatology · 2024-09 · 81 (3) · 562-576
DOI: 10.1016/j.jhep.2024.04.034 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Hepatology, 2024-09. Verfasst von Stephen A Harrison und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU UK; Pinnacle Clinical Research, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Fatty Liver, Fibroblast Growth Factors. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 124 Literaturangaben.
Abstract (Originalsprache)
The worldwide epidemics of obesity, hypertriglyceridemia, dyslipidaemia, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) represent a major economic burden on healthcare systems. Patients with at-risk MASH, defined as MASH with moderate or significant fibrosis, are at higher risk of comorbidity/mortality, with a significant risk of cardiovascular diseases and/or major adverse liver outcomes. Despite a high unmet medical need, there is only one drug approved for MASH. Several drug candidates have reached the phase III development stage and could lead to several potential conditional drug approvals in the coming years. Within the armamentarium of future treatment options, FGF21 analogues hold an interesting position thanks to their pleiotropic effects in addition to their significant effect on both MASH resolution and fibrosis improvement. In this review, we summarise preclinical and clinical data from FGF21 analogues for MASH and explore additional potential therapeutic indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 9DU UK; Pinnacle Clinical Research, San Antonio, Texas, USA.
- Akero Therapeutics, South San Francisco, California, USA.
- Pinnacle Clinical Research, San Antonio, Texas, USA.
- Summit Clinical Research, San Antonio, Texas, USA. Electronic address: julie.dubourg@me.com.
Zitieren
APA
Harrison, S. A., Rolph, T., Knott, M., & Dubourg, J. (2024). FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. Journal of Hepatology, 81(3), 562-576. https://doi.org/10.1016/j.jhep.2024.04.034
Vancouver
Harrison SA, Rolph T, Knott M, Dubourg J. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. Journal of Hepatology. 2024;81(3):562-576. doi:10.1016/j.jhep.2024.04.034
BibTeX
@article{Harrison2024,
author = {Harrison, Stephen A and Rolph, Tim and Knott, Madeline and Dubourg, Julie},
title = {FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond},
journal = {Journal of Hepatology},
year = {2024},
volume = {81},
number = {3},
pages = {562--576},
doi = {10.1016/j.jhep.2024.04.034}
}
EUVIMED